AC Immune (NASDAQ: ACIU) stock is up 27.71% after the company provided preclinical and clinical updates for the SupraAntigen-derived liposomal vaccine candidate. The vaccine candidate offers active and long-lasting protection against pathological forms of Amyloid-beta.  AC Immune report promising ACI-14 study results  AC Immune is finalizing a second phase study […]